药学学报, 2021, 56(1): 80-91
陈诗宇, 赖伟华, 钟诗龙. 新靶点三磷酸腺苷柠檬酸裂解酶(ACLY)抑制剂用于降血脂的研究进展[J]. 药学学报, 2021, 56(1): 80-91.
CHEN Shi-yu, LAI Wei-hua, ZHONG Shi-long. Research progress on ATP citrate lyase (ACLY) inhibitors for decreasing blood lipids[J]. Acta Pharmaceutica Sinica, 2021, 56(1): 80-91.

陈诗宇1,2, 赖伟华1, 钟诗龙1,2,3
1. 广东省人民医院 (广东省医学科学院) 药学部, 广东 广州 510080;
2. 华南理工大学生物科学与工程学院, 广东 广州 510006;
3. 广东省人民医院 (广东省医学科学院) 广东省冠心病防治研究重点实验室, 广东 广州 510080
关键词:    ATP柠檬酸裂解酶      抑制剂      血脂      胆固醇      乙酰辅酶A     
Research progress on ATP citrate lyase (ACLY) inhibitors for decreasing blood lipids
CHEN Shi-yu1,2, LAI Wei-hua1, ZHONG Shi-long1,2,3
1. Department of Pharmacy, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, China;
2. School of Biology and Biological Engineering, South China University of Technology, Guangzhou 510006, China;
3. Guangdong Provincial Key Laboratory of Coronary Heart Disease Prevention, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, China
Cardiovascular disease is a principal cause of morbidity and death in the world. Although drug therapy has made great progress in the past few decades, there are still many deficiencies in the prevention and treatment of cardiovascular disease. Dyslipidemia is still a common risk feature and is not sufficiently controlled. A growing body of evidence suggests that the occurrence and development of cardiovascular disease is associated with many associated risk factors, such as higher low-density lipoprotein levels, lower high-density lipoprotein levels and high triglyceride levels. A number of clinical trials in patients with dyslipidemia have shown that actively decreasing low density lipoprotein cholesterol can significantly decrease cardiovascular events. ATP citrate lyase (ACLY) is a cytoplasmic homo-tetrameric enzyme. In the presence of adenosine triphosphate (ATP), ACLY catalyzes the conversion of citric acid and coenzyme A to acetyl-CoA and oxalyl acetate. ACLY is the main enzyme for the production of cytoplasmic acetyl-CoA, and cytoplasmic acetyl-CoA is the precursor required for de novo synthesis of cholesterol and fatty acids. Therefore, it is possible to reduce the production of acetyl-CoA and reduce the levels of cholesterol and triglycerides by inhibiting ACLY. ACLY can be used as a molecular target for reducing blood lipids, and there are an increasing number of studies on ACLY inhibitors. In this paper, the structure and mechanism of ACLY and its relationship with lipid metabolism are briefly introduced, and we review some current ACLY inhibitors.
Key words:    ATP citrate lyase    inhibitor    blood lipid    cholesterol    acetyl-CoA   
收稿日期: 2020-06-09
DOI: 10.16438/j.0513-4870.2020-0932
基金项目: 国家自然科学基金资助项目(81872934,81673514);广东省重点领域研发计划(2019B020229003);广东省科技计划(2017B0303314041).
通讯作者: 钟诗龙,Tel:86-20-83827812-60298;E-mail:gdph_zhongsl@gd.gov.cn
Email: gdph_zhongsl@gd.gov.cn
PDF(1260KB) Free
陈诗宇  在本刊中的所有文章
赖伟华  在本刊中的所有文章
钟诗龙  在本刊中的所有文章

[1] Liu S, Li Y, Zeng X, et al. Burden of cardiovascular diseases in China, 1990-2016:findings from the 2016 global burden of disease study[J]. JAMA Cardiol, 2019, 4:342-352.
[2] Virani SS, Alonso A, Benjamin EJ, et al. Heart disease and stroke statistics-2020 update:a report from the American Heart Association[J]. Circulation, 2020, 141:e139-e596.
[3] Ma LY, Chen WW, Gao RL, et al. China cardiovascular diseases report 2018:an updated summary[J]. J Geriatr Cardiol, 2020, 17:1-8.
[4] Kong YY, Li GQ, Zhang WJ, et al. Nicotinamide phosphoribosyltransferase aggravates inflammation and promotes atherosclerosis in ApoE knockout mice[J]. Acta Pharmacol Sin, 2019, 40:1184-1192.
[5] Afshinnia F, Pennathur S. Lipids and cardiovascular risk with CKD[J]. Clin J Am Soc Nephrol, 2020, 15:5-7.
[6] Ito F, Ito T. High-density lipoprotein (HDL) triglyceride and oxidized HDL:new lipid biomarkers of lipoprotein-related atherosclerotic cardiovascular disease[J]. Antioxidants (Basel), 2020, 9:362.
[7] Feng X, Zhang L, Xu S, et al. ATP-citrate lyase (ACLY) in lipid metabolism and atherosclerosis:an updated review[J]. Prog Lipid Res, 2020, 77:101006.
[8] Bartlett J, Predazzi IM, Williams SM, et al. Is isolated low high-density lipoprotein cholesterol a cardiovascular disease risk factor? New insights from the framingham offspring study[J]. Circ Cardiovasc Qual Outcomes, 2016, 9:206-212.
[9] Generoso G, Janovsky CCPS, Bittencourt MS. Triglycerides and triglyceride-rich lipoproteins in the development and progression of atherosclerosis[J]. Curr Opin Endocrinol Diabetes Obes, 2019, 26:109-116.
[10] Zhu JR, Gao RL, Zhao SP, et al. Guidelines for the prevention and treatment of dyslipidemia in Chinese adults (revised in 2016)[J]. Chin Circ J (中国循环杂志), 2016, 16:15-35.
[11] Zhang M, Deng Q, Wang L, et al. Prevalence of dyslipidemia and achievement of low-density lipoprotein cholesterol targets in Chinese adults:a nationally representative survey of 163641 adults[J]. Int J Cardiol, 2018, 260:196-203.
[12] Taylor FC, Huffman M, Ebrahim S. Statin therapy for primary prevention of cardiovascular disease[J]. JAMA, 2013, 310:2451-2452.
[13] Bair TL, May HT, Knowlton KU, et al. Predictors of statin intolerance in patients with a new diagnosis of atherosclerotic cardiovascular disease within a large integrated health care institution:the IMPRES study[J]. J Cardiovasc Pharmacol, 2020, 75:426-431.
[14] Lemus HN, Mendivil CO. Adenosine triphosphate citrate lyase:emerging target in the treatment of dyslipidemia[J]. J Clin Lipidol, 2015, 9:384-389.
[15] Burke AC, Huff MW. ATP-citrate lyase:genetics, molecular biology and therapeutic target for dyslipidemia[J]. Curr Opin Lipidol, 2017, 28:193-200.
[16] Pinkosky SL, Groot PHE, Lalwani ND, et al. Targeting ATP-citrate lyase in hyperlipidemia and metabolic disorders[J]. Trends Mol Med, 2017, 23:1047-1063.
[17] Sun T, Hayakawa K, Fraser ME. ADP-Mg(2+) bound to the ATP-grasp domain of ATP-citrate lyase[J]. Acta Crystallogr Sect F Struct Biol Cryst Commun, 2011, 67:1168-1172.
[18] Sivanand S, Rhoades S, Jiang Q, et al. Nuclear acetyl-CoA production by ACLY promotes homologous recombination[J]. Mol Cell, 2017, 67:252-265.e6.
[19] Hügler M, Sievert SM. Beyond the Calvin cycle:autotrophic carbon fixation in the ocean[J]. Ann Rev Mar Sci, 2011, 3:261-289.
[20] Chypre M, Zaidi N, Smans K. ATP-citrate lyase:a mini-review[J]. Biochem Biophys Res Commun, 2012, 422:1-4.
[21] Wei J, Leit S, Kuai J, et al. An allosteric mechanism for potent inhibition of human ATP-citrate lyase[J]. Nature, 2019, 568:566-570.
[22] Verschueren KHG, Blanchet C, Felix J, et al. Structure of ATP citrate lyase and the origin of citrate synthase in the Krebs cycle[J]. Nature, 2019, 568:571-575.
[23] Sun T, Hayakawa K, Bateman KS, et al. Identification of the citrate-binding site of human ATP-citrate lyase using X-ray crystallography[J]. J Biol Chem, 2010, 285:27418-27428.
[24] Granchi C. ATP citrate lyase (ACLY) inhibitors:an anti-cancer strategy at the crossroads of glucose and lipid metabolism[J]. Eur J Med Chem, 2018, 157:1276-1291.
[25] Zu XY, Zhang QH, Liu JH, et al. ATP citrate lyase inhibitors as novel cancer therapeutic agents[J]. Recent Pat Anticancer Drug Discov, 2012, 7:154-167.
[26] Fan F, Williams HJ, Boyer JG, et al. On the catalytic mechanism of human ATP citrate lyase[J]. Biochemistry, 2012, 51:5198-5211.
[27] Wang Q, Li S, Jiang L, et al. Deficiency in hepatic ATP-citrate lyase affects VLDL-triglyceride mobilization and liver fatty acid composition in mice[J]. J Lipid Res, 2010, 51:2516-2526.
[28] Wei X, Schultz K, Bazilevsky GA, et al. Molecular basis for acetyl-CoA production by ATP-citrate lyase[J]. Nat Struct Mol Biol, 2020, 27:33-41.
[29] Singh P, Saxena R, Srinivas G, et al. Cholesterol biosynthesis and homeostasis in regulation of the cell cycle[J]. PLoS One, 2013, 8:e58833.
[30] Gunasekaran B, Shukor MY. HMG-CoA reductase as target for drug development[J]. Methods Mol Biol, 2020, 2089:245-250.
[31] Kuhajda FP. Fatty-acid synthase and human cancer:new perspectives on its role in tumor biology[J]. Nutrition, 2000, 1:202-208.
[32] Unterlass JE, Curtin NJ. Warburg and Krebs and related effects in cancer[J]. Expert Rev Mol Med, 2019, 21:e4.
[33] Hatzivassiliou G, Zhao F, Bauer DE, et al. ATP citrate lyase inhibition can suppress tumor cell growth[J]. Cancer Cell, 2005, 8:311-321.
[34] Turyn J, Schlichtholz B, Dettlaff-Pokora A, et al. Increased activity of glycerol 3-phosphate dehydrogenase and other lipogenic enzymes in human bladder cancer[J]. Horm Metab Res, 2003, 35:565-569.
[35] Szutowicz A, Kwiatkowski J, Angielski S. Lipogenetic and glycolytic enzyme activities in carcinoma and nonmalignant diseases of the human breast[J]. Br J Cancer, 1979, 39:681-687.
[36] Beckner ME, Fellows-Mayle W, Zhang Z, et al. Identification of ATP citrate lyase as a positive regulator of glycolytic function in glioblastomas[J]. Int J Cancer, 2010, 126:2282-2295.
[37] Xin M, Qiao Z, Li J, et al. miR-22 inhibits tumor growth and metastasis by targeting ATP citrate lyase:evidence in osteosarcoma, prostate cancer, cervical cancer and lung cancer[J]. Oncotarget, 2016, 7:44252-44265.
[38] Bauer DE, Hatzivassiliou G, Zhao F, et al. ATP citrate lyase is an important component of cell growth and transformation[J]. Oncogene, 2005, 24:6314-6322.
[39] Cheng C, Geng F, Cheng X, et al. Lipid metabolism reprogramming and its potential targets in cancer[J]. Cancer Commun (Lond), 2018, 38:27.
[40] Watson JA, Fang M, Lowenstein JM. Tricarballylate and hydroxycitrate:substrate and inhibitor of ATP:citrate oxaloacetate lyase[J]. Arch Biochem Biophys, 1969, 135:209-217.
[41] Cheema-Dhadli S, Halperin ML, Leznoff CC. Inhibition of enzymes which interact with citrate by (-) hydroxycitrate and 1,2,3,-tricarboxybenzene[J]. Eur J Biochem, 1973, 38:98-102.
[42] Hamilton JG, Sullivan AC, Kritchevsky D, et al. Hupolipidemic activity of (-)-hydroxycitrate[J]. Lipids, 1977, 12:1-9.
[43] Sullivan AC, Singh M, Srere PA, et al. Reactivity and inhibitor potential of hydroxycitrate isomers with citrate synthase, citrate lyase, and ATP citrate lyase[J]. J Biol Chem, 1977, 252:7583-7590.
[44] van Loon LJ, van Rooijen JJ, Niesen B, et al. Effects of acute (-)-hydroxycitrate supplementation on substrate metabolism at rest and during exercise in humans[J]. Am J Clin Nutr, 2000, 72:1445-1450.
[45] Berkhout TA, Havekes LM, Pearce NJ, et al. The effect of (-)-hydroxycitrate on the activity of the low-density-lipoprotein receptor and 3-hydroxy-3-methylglutaryl-CoA reductase levels in the human hepatoma cell line Hep G2[J]. Biochem J, 1990, 272:181-186.
[46] Atkinson LL, Kelly SE, Russell JC, et al. MEDICA 16 inhibits hepatic acetyl-CoA carboxylase and reduces plasma triacylglycerol levels in insulin-resistant JCR:LA-cp rats[J]. Diabetes, 2002, 51:1548-1555.
[47] Kanao T, Fukui T, Atomi H, et al. Kinetic and biochemical analyses on the reaction mechanism of a bacterial ATP-citrate lyase[J]. Eur J Biochem, 2002, 269:3409-3416.
[48] Bar-Tana J, Ben-Shoshan S, Blum J, et al. Synthesis and hypolipidemic and antidiabetogenic activities of beta,beta,beta',beta'-tetrasubstituted, long-chain dioic acids[J]. J Med Chem, 1989, 32:2072-2084.
[49] Rose-Kahn G, Bar-Tana J. Inhibition of lipid synthesis by beta beta'-tetramethyl-substituted, C14-C22, alpha, omega-dicarboxylic acids in cultured rat hepatocytes[J]. J Biol Chem, 1985, 260:8411-8415.
[50] Rose-Kahn G, Bar-Tana J. Inhibition of rat liver acetyl-CoA carboxylase by beta, beta'-tetramethyl-substituted hexadecanedioic acid (MEDICA 16)[J]. Biochim Biophys Acta, 1990, 1042:259-264.
[51] Saxty BA, Novelli R, Dolle RE, et al. Synthesis and evaluation of (+) and (-)-2,2-difluorocitrate as inhibitors of rat-liver ATP-citrate lyase and porcine-heart aconitase[J]. Eur J Biochem, 1991, 202:889-896.
[52] Dolle RE, McNair D, Hughes MJ, et al. ATP-citrate lyase as a target for hypolipidemic intervention. Sulfoximine and 3-hydroxy-beta-lactam containing analogues of citric acid as potential tight-binding inhibitors[J]. J Med Chem, 1992, 35:4875-4884.
[53] Brusilow WS, Peters TJ. Therapeutic effects of methionine sulfoximine in multiple diseases include and extend beyond inhibition of glutamine synthetase[J]. Expert Opin Ther Targets, 2017, 21:461-469.
[54] Chan GW, Francis T, Thureen DR. Purpurone, an inhibitor of ATP-citrate lyase:a novel alkaloid from the marine sponge Iotrochota sp[J]. J Org Chem, 1993, 58:2544-2546.
[55] Li Q, Fan A, Lu Z, et al. One-pot AgOAc-mediated synthesis of polysubstituted pyrroles from primary amines and aldehydes:application to the total synthesis of purpurone[J]. Org Lett, 2010, 12:4066-4069.
[56] al-Shurbaji A, Skorve J, Berge RK, et al. Effect of 3-thiadicarboxylic acid on lipid metabolism in experimental nephrosis[J]. Arterioscler Thromb, 1993, 13:1580-1586.
[57] Berge RK, Aarsland A, Kryvi H, et al. Alkylthioacetic acid (3-thia fatty acids)-a new group of non-β-oxidizable, peroxisome-inducing fatty acid analogues. I. A study on the structural requirements for proliferation of peroxisomes and mitochondria in rat liver[J]. Biochim Biophys Acta, 1989, 1004:345-356.
[58] Oleynek JJ, Barrow CJ, Burns MP, et al. Anthrones, naturally occurring competitive inhibitors of adenosine-triphosphate-citrate lyase[J]. Drug Dev Res, 1995, 36:35-42.
[59] Dolle RE, Gribble A, Wilkes T, et al. Synthesis of novel thiol-containing citric acid analogs. Kinetic evaluation of these and other potential active-site-directed and mechanism-based inhibitors of ATP citrate lyase[J]. J Med Chem, 1995, 38:537-543.
[60] Li JJ, Wang H, Tino JA, et al. 2-Hydroxy-N-arylbenzenesulfonamides as ATP-citrate lyase inhibitors[J]. Bioorg Med Chem Lett, 2007, 17:3208-3211.
[61] Gribble AD, Ife RJ, Shaw A, et al. ATP-citrate lyase as a target for hypolipidemic intervention. 2. Synthesis and evaluation of (3R,5S)-omega-substituted-3-carboxy-3,5-dihydroxyalkanoic acids and their gamma-lactone prodrugs as inhibitors of the enzyme in vitro and in vivo[J]. J Med Chem, 1998, 41:3582-3595.
[62] Gribble AD, Dolle RE, Shaw A, et al. ATP-citrate lyase as a target for hypolipidemic intervention. Design and synthesis of 2-substituted butanedioic acids as novel, potent inhibitors of the enzyme[J]. J Med Chem, 1996, 39:3569-3584.
[63] Istvan ES, Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA reductase[J]. Science, 2001, 292:1160-1164.
[64] Cheng H, Nie R, Wang WQ, et al. Research progress on structural modification of antimycin A[J]. Chin J Org Chem (有机化学), 2017, 37:1368-1381.
[65] Schilling G, Berti D, Kluepfel D. Antimycin A components. Ⅱ. Identification and analysis of antimycin A fractions by pyrolysis-gas liquid chromatography[J]. J Antibiot (Tokyo), 1970, 23:81-90.
[66] Barrow CJ, Oleynek JJ, Marinelli V, et al. Antimycins, inhibitors of ATP-citrate lyase, from a Streptomyces sp[J]. J Antibiot (Tokyo), 1997, 50:729-733.
[67] Pearce NJ, Yates JW, Berkhout TA, et al. The role of ATP citrate-lyase in the metabolic regulation of plasma lipids. Hypolipidaemic effects of SB-204990, a lactone prodrug of the potent ATP citrate-lyase inhibitor SB-201076[J]. Biochem J, 1998, 334:113-119.
[68] Gribble AD, Groot PHE, Shaw AN, et al. Phenylderivate as inhibitors of ATP citrate lyase:US, 5447954[P]. 1995-9-5.
[69] Atsushi H, Koichiro T, Shigeru U, et al. ATP-citrate lyase inhibiting substances of BE-063437 type and method for producing the same:JP, 2001261682[P]. 2001-09-26.
[70] Burke AC, Telford DE, Huff MW. Bempedoic acid:effects on lipoprotein metabolism and atherosclerosis[J]. Curr Opin Lipidol, 2019, 30:1-9.
[71] Pinkosky SL, Newton RS, Day EA, et al. Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis[J]. Nat Commun, 2016, 7:13457.
[72] Ray KK, Laufs U, Cosentino F, et al. The year in cardiology:cardiovascular prevention[J]. Eur Heart J, 2020, 41:1157-1163.
[73] Thompson PD, Rubino J, Janik MJ, et al. Use of ETC-1002 to treat hypercholesterolemia in patients with statin intolerance[J]. J Clin Lipidol, 2015, 9:295-304.
[74] Samsoondar JP, Burke AC, Sutherland BG, et al. Prevention of diet-induced metabolic dysregulation, inflammation, and atherosclerosis in ldlr(-/-) mice by treatment with the ATP-citrate lyase inhibitor bempedoic acid[J]. Arterioscler Thromb Vasc Biol, 2017, 37:647-656.
[75] Burke AC, Telford DE, Sutherland BG, et al. Bempedoic acid lowers low-density lipoprotein cholesterol and attenuates atherosclerosis in low-density lipoprotein receptor-deficient (LDLR(+/-) and LDLR(-/-)) yucatan miniature pigs[J]. Arterioscler Thromb Vasc Biol, 2018, 38:1178-1190.
[76] Filippov S, Pinkosky SL, Newton RS. LDL-cholesterol reduction in patients with hypercholesterolemia by modulation of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase[J]. Curr Opin Lipidol, 2014, 25:309-315.
[77] Bove M, Cicero AFG, Borghi C, et al. Emerging drugs for the treatment of hypercholesterolemia[J]. Expert Opin Emerg Drugs, 2019, 24:63-69.
[78] Sharpe LJ, Brown AJ. Controlling cholesterol synthesis beyond 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR)[J]. J Biol Chem, 2013, 288:18707-18715.
[79] Ballantyne CM, Davidson MH, Macdougall DE, et al. Efficacy and safety of a novel dual modulator of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase in patients with hypercholesterolemia[J]. J Am Coll Cardiol, 2013, 62:1154-1162.
[80] Elam MB, Majumdar G, Mozhui K, et al. Patients experiencing statin-induced myalgia exhibit a unique program of skeletal muscle gene expression following statin re-challenge[J]. PLoS One, 2017, 12:e0181308.
[81] Ference BA, Ray KK, Catapano AL, et al. Mendelian randomization study of ACLY and cardiovascular disease[J]. N Engl J Med, 2019, 380:1033-1042.
[82] Ray KK, Bays HE, Catapano AL, et al. Safety and efficacy of bempedoic acid to reduce LDL cholesterol[J]. N Engl J Med, 2019, 380:1022-1032.
1.马贝贝, 卞聪, 洪斌, 杜郁, 陈晓芳.基于高密度脂蛋白的抗动脉粥样硬化小分子药物研究现状[J]. 药学学报, 2018,53(3): 328-335